TRPM6 and TRPM7 are members of the melastatin-related transient receptor potential (TRPM) subfamily of ion channels. Deletion of either gene in mice is embryonically lethal. TRPM6/7 are the only known examples of single polypeptides containing both an ion channel pore and a serine/threonine kinase (chanzyme). Here we show that the C-terminal kinase domain of TRPM6 is cleaved from the channel domain in a cell type-specific fashion and is active. Cleavage requires that the channel conductance is functional. The cleaved kinase translocates to the nucleus, where it is strictly localized and phosphorylates specific histone serine and threonine (S/T) residues. TRPM6-cleaved kinases (M6CKs) bind subunits of the protein arginine methyltransferase 5 (PRMT5) molecular complex that make important epigenetic modifications by methylating histone arginine residues. Histone phosphorylation by M6CK results in a dramatic decrease in methylation of arginines adjacent to M6CK-phosphorylated amino acids. Knockout of TRPM6 or inactivation of its kinase results in global changes in histone S/T phosphorylation and changes the transcription of hundreds of genes. We hypothesize that M6CK associates with the PRMT5 molecular complex in the nucleus, directing M6CK to a specific genomic location and providing site-specific histone phosphorylation. M6CK histone phosphorylation, in turn, regulates transcription by attenuating the effect of local arginine methylation.
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TRPM6 | TRPM7 | kinase | ion channel | PRMT5 A mong the several hundred genes encoding cation channels, the melastatin-related transient receptor potential family members TRPM6 and TRPM7 are unique in also being serine/ threonine (S/T) kinases (1) . The TRPM6 channel kinase was brought to greater attention when mutations in this chanzyme were found to be the cause of familial hypomagnesemia with secondary hypocalcemia (HSH; see ref. 2 
for a recent review).
Characterized by severe hypomagnesemia, infants with HSH suffer tetany and refractory seizures shortly after birth, resulting in permanent neurological damage or death if untreated. The mechanisms by which mutations in TRPM6 lead to HSH are unknown, although several studies stress the importance of TRPM6-mediated Mg 2+ conductance (3) (4) (5) . Importantly, global TRPM6 disruption in mice is embryonic lethal (6, 7) . Mice with loss of TRPM6 at intermediate developmental time points manifest a reduced life span and skeletal deformations, in addition to mild hypomagnesemia (5) . These data indicate that, much like TRPM7 (8), TRPM6 may be critical for normal, developmental, tissue-specific regulation of gene activity.
Recently, our laboratory uncovered a signaling pathway mediated by TRPM7, a channel sharing 52% homology with TRPM6, whereby the functional S/T kinase at the carboxyl terminus of TRPM7 is proteolytically cleaved from the channel domain, forming cleaved kinase fragments (M7CKs) that translocate to the nucleus (9) . There, M7CKs bind components of chromatin-remodeling complexes to ultimately phosphorylate specific S/T residues of histones, regulate selected histone acetylation, and modulate gene transcription.
The present study investigates whether the TRPM6 kinase may play a similar role in cells to direct gene expression. Although TRPM6 is known to undergo autophosphorylation, little else is understood regarding the phosphorylation targets of TRPM6 and the functional role of its kinase (10) (11) (12) . Furthermore, whether there are links between the conductance of the TRPM6 channel and the activity of its kinase is unknown.
Here we show that the TRPM6 kinase is cleaved from the channel domain in a cell type-specific fashion and that kinase cleavage requires the TRPM6 channel's conductance. TRPM6-cleaved kinases (M6CKs) localize strictly to the nucleus and phosphorylate select S/T residues of histones. M6CKs bind the protein arginine methyltransferase 5 (PRMT5) molecular complex, which has been shown to direct important epigenetic modifications by methylating histone arginines (13) . Histone phosphorylation by M6CK results in a dramatic decrease in the methylation of arginine residues adjacent to M6CK-phosphorylated amino acids. Knockout of the TRPM6 gene results in global changes in histone S/T phosphorylation and in the transcriptional activity of hundreds of genes. We hypothesize that the association of M6CK with the Significance Ion channels are proteins that span the cell's membrane and affect the rapid transfer of ions. Kinases are proteins that transfer a phosphate from ATP to specific substrates. In mammals, there are two unusual proteins, melastatin-related transient receptor potential (TRPM)6 and TRPM7, that have both functions. Here we show that TRPM6's kinase and channel domains are functionally connected: The kinase is cleaved from the channel domain, and this cleavage depends on the channel being operational. The freed kinase moves to the nucleus and phosphorylates specific histone residues. This results in a dramatic decrease in methylation of adjacent arginine amino acids shown to be critical epigenetic marks for cell differentiation and embryonic development. TRPM6's kinase-dependent histone posttranslational modifications change the transcription of hundreds of genes.
PRMT5 molecular complex in the nucleus directs M6CK to a specific genomic location to provide site-specific histone phosphorylation to attenuate the effect of arginine methylation on transcription.
Results
The C Terminus of TRPM6 Is Proteolytically Cleaved in Vivo, Releasing the Kinase from the Transmembrane Domains. To characterize the endogenous TRPM6 protein and decrease off-target antibody labeling, we first immunoprecipitated the protein from 2 to 3 × 10 7 cells using a rabbit antibody (made to the C-terminal 14 amino acids of TRPM6; αM6C14), followed by Western blotting (WB) with a mouse antibody recognizing the C-terminal epitope. We tested a number of cell types and found three cell lines where native TRPM6 protein expression was robustly detected (Fig. 1A) . In addition to a 230-kDa band corresponding to full-length TRPM6, we detected several lower-molecular mass bands (Fig. 1A) . As with TRPM7 (9), we suggest that the endogenous TRPM6 molecule is proteolytically cleaved, freeing the kinase domain from the channel moiety. All subsequent experiments were performed in HEK 293T (293T) cells.
Lower-molecular mass bands appear to be true fragments of TRPM6, as deletion of the TRPM6 gene in 293T cells eliminated all protein bands detected by WB (Fig. 1A) . Stable ectopic expression of C-terminally HA-tagged TRPM6 in 293T cells also produced multiple M6CKs, detected by HA-IP (immunoprecipitation) followed by HA-WB (Fig. 1B) . We attribute the observation that overexpressed TRPM6 demonstrates more cleaved fragments than endogenous TRPM6 to the fact that the recognition epitope of the mouse monoclonal antibody used for detection of endogenous TRPM6 is located upstream of amino acid ∼1400 (e.g., this antibody does not recognize fragments cleaved between amino acid 1400 and the C terminus; Fig. S1 ). It is also likely that the avidity of the highly selected HA antibody is superior to that of the mouse monoclonal antibody.
To reveal all endogenous TRPM6 kinase-containing fragments, we used CRISPR-Cas9 techniques to incorporate a 2×HA epitope tag sequence into TRPM6 immediately before the stop codon (293T-M6 HA ). The cleavage pattern of endogenous HA-tagged TRPM6 protein was identical to that of ectopically expressed protein (Fig. 1B) . This result argues against the possibility that the detected TRPM6 fragments are products of alternative splicing. In addition, we conclude that these fragments are not the result of proteolysis during IP, because their relative abundance did not vary with time over 2 to 17 h. We next sought to investigate whether the channel activity of TRPM6 is required for cleavage of M6CKs from the channel domain. Using CRISPR-Cas9, we introduced a pore mutation in the sixth transmembrane domain of TRPM6 in 293T-M6 HA cells (amino acids 1063 to 1065, NLL to FAP), which eliminated the channel's conductance (Fig. S2 ). We previously demonstrated that an identical TRPM7 pore mutant acted as a dominant negative, preventing ion conduction by the native channel (14) . We found that pore mutations in TRPM6 did not effect TRPM6 expression but completely abolished endogenous protein cleavage (Fig. 1C) . These data support the conclusion that TRPM6's C terminus is proteolytically cleaved in vivo and suggest that conductance of the TRPM6 channel is required for kinase cleavage. Hence, channel activity regulation will be mirrored in kinase release.
Nuclear Localization of M6CKs. The heterologously expressed fulllength TRPM6 is localized to intracellular vesicles ( Fig. 2A ) similar to TRPM7-containing vesicles (15) and colocalizes with TRPM7. Unfortunately, very low expression of endogenous TRPM6 hindered our ability to further resolve its cellular location, even with high-avidity HA antibodies. M6CKs cleaved at amino acids 1100, 1225, and 1365 were localized strictly in the nucleus by immunofluorescence (Fig. 2B) . M6CK cleaved at amino acid 1658 was localized to both the nucleus and cytoplasm. Analysis of the TRPM6 amino acid sequence (nls-mapper.iab. keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) predicted several putative nuclear localization signals (NLSs) on the C terminus after the sixth transmembrane domain, that may provide the basis for importin-mediated M6CK nuclear localization (see the position for the highest-score NLS in Fig. 1B) . In interphase cells, nuclear M6CKs display a granular pattern, suggesting M6CK binding to specific chromatin loci (Fig. 2B ). This interpretation was supported by the observation that M6CK extraction from nuclei required high salt concentrations (0.4 to 0.6 M NaCl), similar to conditions for chromatin-bound nuclear proteins. In mitotic cells, M6CK was excluded from chromatin structures (Fig. 2C ).
M6CKs Tune Gene Transcription. We previously demonstrated that M7CKs translocate to the nucleus to regulate the activity of hundreds of genes (9) . The nuclear localization of M6CKs and the structural similarity of M6/M7 channel kinases motivated us to test the effect of TRPM6 on gene activity. We performed microarray analysis for differential gene expression in WT and TRPM6 −/− 293T cells. Microarray data (Dataset S1) demonstrated that cellular deletion of TRPM6 is associated with changes in expression of more than 2,000 genes. Functional annotation of differentially expressed genes (16) reveals significant enrichment of genes with nuclear and organelle lumen function (Table S1 ). To further validate our microarray data, we selected several genes that were highly down-regulated in TRPM6
−/− cells and performed gene expression analysis with quantitative PCR (qPCR). Comparison of gene expression in WT 293T and 293T-TRPM6
−/− cells confirmed the microarray data (Fig. 3) . To distinguish whether the activity of the TRPM6 channel or its kinase was responsible for modulating gene expression, we generated 293T cells with a point mutation in the phosphotransferase domain (K1804A) of TRPM6. As shown in Fig. S2 , this mutation eliminated TRPM6 kinase activity but did not change the channel's conductance or endogenous full-length TRPM6 protein expression. TRPM6 kinase inactivation reproduces TRPM6 −/− -dependent changes in gene activity (Fig. 3) . We conclude that TRPM6's kinase activity is responsible for TRPM6 deletion-dependent alterations in gene expression.
M6CK Binds Components of the PRMT5 Complex.
To gain insight into the cellular mechanisms regulated by M6CKs, we studied the TRPM6 interactome, harnessing tandem affinity purification methodology, followed by mass spectrometry identification of proteins copurified with TRPM6 (17) . To reveal M6CK interactors, we chose as bait a full-length, C-terminally tagged TRPM6 stably expressed in 293T cells, as this tagged protein has the same cleavage pattern as endogenous TRPM6 (Fig. 1B) . These experiments showed a substantial proportion of putative TRPM6 interactors to be nuclear proteins (Dataset S2). The most striking finding in purified TRPM6 molecular complexes was the abundance of PRMT5 and accessory subunits of the PRMT5 methylosome molecular complex WDR77 (13) and ICLN (pICln), along with core spliceosomal proteins (Dataset S2).
To examine whether endogenous TRPM6 complexes with the identified presumed interactors, we immunoprecipitated endogenous TRPM6 HA from 293T-M6 HA cells with HA antibody and performed WB for endogenous candidate proteins. WT 293T cells were used as controls for the determination of nonspecific binding. Fig. 4A demonstrates that PRMT5, WDR77, and ICLN were specifically bound to endogenous TRPM6. To test whether the PRMT5 complex specifically interacts with M6CK, we immunoprecipitated stably, ectopically expressed, FLAG-tagged fulllength TRPM6 and M6CK. We found that specific binding of endogenous PRMT5 and subunits of the PRMT5 complex to M6CK cleaved at amino acid 1365 (Fig. 4B) . M6CK cleaved at amino acid 1658 also binds components of the PRMT5 complex, which suggests that the binding site is located on the C terminus, proximal to the kinase or within the kinase domain. Hence, M6CK binds components of the PRMT5 complex.
M6CK Phosphorylates Specific S/T Residues of Histones and Attenuates
Methylation of Adjacent Arginine Residues. We first tested whether bound PRMT5, WDR77, and ICLN were phosphorylated by M6CK in vitro. Epitope-tagged, ectopically coexpressed, and immunoprecipitated M6CK did not phosphorylate coimmunoprecipitated PRMT5, WDR77, or ICLN. We were also unable to detect phosphorylation of purified PRMT5, WDR77, and ICLN proteins with purified M6CK.
PRMT5 is known to symmetrically dimethylate arginine residues in many proteins, including nuclear proteins. This posttranslational modification regulates the functional activity of these proteins and is associated with transcriptional regulation (primarily inhibition), apoptosis and cell-cycle progression, DNA repair, and developmental gene regulation (18, 19) . Great attention has been paid to PRMT5-mediated methylation of specific arginine residues in histones. These modifications alter chromatin structure by affecting the recruitment of nonhistone proteins that modulate the accessibility of genomic DNA, thus tuning gene expression involved in cell-cycle progression, differentiation, and DNA repair, among other cellular functions (20) (21) (22) (23) . As we recently demonstrated, the highly homologous M7CK phosphorylates specific histone S/T residues, enhancing neighboring lysine acetylation to alter gene expression (9) . Analogously, we hypothesize that binding of M6CK to the PRMT5 complex or its histone-associated subunits may target M6CKs for S/T phosphorylation at specific chromatin locations, adjacent to PRMT5-methylated arginine residues. Fig. S3 demonstrates that purified M6CK effectively phosphorylates purified histones in vitro. We next compared M6CK-dependent in vivo histone phosphorylation in WT and TRPM6-KO 293T cells. Using phospho-specific antibodies, we probed S/T phosphorylation at residues neighboring arginines known to be methylated by PRMT5 (18) . In the same chromatin preparations, we tested histone arginine methylation using antibodies specific for selected symmetrically dimethylated arginines (Arg-me2). These experiments demonstrate that knockout of TRPM6 results in a global decrease in phosphorylation of H2A-S1 and H4-S1 (Fig. 5A) . To support these findings, we also demonstrated that H2A-S1 and H4-S1 were directly phosphorylated by purified M6CK in preparations of purified H2A and H4 histones (Fig. 5A) . Coinciding with serine dephosphorylation, deletion of TRPM6 resulted in a dramatic increase of global symmetric methylation of H2A-R3 and H4-R3, arginines proximal to dephosphorylated serines. For H3 histones, loss of TRPM6 resulted in dephosphorylation of H3-Thr3 and H3-Thr6, concurrent with a substantial increase in the symmetric methylation of H3-R2 and H3-R8 (Fig. 5B) . Again, M6CK directly phosphorylated H3-Thr3 and H3-Thr6 (Fig. 5B) .
We previously demonstrated that TRPM7 kinase phosphorylated H3-S10 and H3-S28 in vivo but did not affect T11 phosphorylation (9). Here we tested phosphorylation of these residues -11.00 -9.00 -7.00 -5.00 -3.00 -1.00
RNA expression, Log(2) fold changes in TRPM6-KO cells to investigate whether these two homologous kinases have distinct histone phosphorylation patterns. Unlike TRPM7, we found that loss of TRPM6 resulted in hyperphosphorylation of H3-S10 and H3-T11, implying that TRPM6 does not phosphorylate these serines directly but rather inhibits a separate kinase that modifies these residues (Fig. 5C ). This conclusion was corroborated by our finding that purified M6CK did not phosphorylate purified H3-S10 and H3-T11 in vitro (Fig.  5C ). In contrast to TRPM7, phosphorylation of H3-S28 was not affected by deletion of TRPM6 (Fig. 5C ), and thus served as an intrinsic control. Antibody recognition of methylated lysine residues may be compromised when an adjacent residue is phosphorylated (24). Similarly, it is possible that a reduction in S/T phosphorylation might mimic adjacent arginine hypermethylation.
To test this possibility, we pretreated histone extracts with λ-phosphatase and found that the increased Arg-me2 in TRPM6
−/− cells was not affected by histone dephosphorylation. We also tested histone phosphorylation and methylation in cells where endogenous TRPM6 kinase was inactivated by a selective point mutation in TRPM6 (Materials and Methods and Fig. S2 ). The kinase-dead mutation attenuated the same histone phosphorylation and enhanced arginine methylation as seen in knockouts of WT TRPM6 (Fig. 5D) . We conclude that M6CK itself is responsible for modulation of histone phosphorylation and methylation. This conclusion is supported by the finding that overexpression of active M6CK in TRPM6-KO cells reversed TRPM6-dependent histone phosphorylation and methylation to the WT level (Fig. S4) . These data indicate that M6CK can directly phosphorylate selected S/T residues in histones and abrogate symmetric methylation of the neighboring arginine residues.
The PRMT5-WDR77-ICLN complex is also critical for core spliceosome biogenesis (25) (26) (27) . Using co-IP, we found that TRPM6 binds other components of the core spliceosome: SNRPD1, SNRPD2, HNRNPA2B1, SmBB′, and the splicing effector Matrin3 (28) (Dataset S2). These findings suggest that M6CK may participate in RNA splicing regulation, an avenue that will require more detailed future study.
Discussion
We demonstrated that fragments of the TRPM6 C terminus containing the functional protein kinase are cleaved from the channel domain in a cell type-specific fashion. We also demonstrated that mutations ablating TRPM6 channel activity (pore mutants) preclude kinase cleavage, implying that TRPM6 channel activity plays a critical role in the generation of M6CKs. This finding suggests that ions permeating the channel activate or translocate proteases to release the kinase from the channel. We recently demonstrated that the bulk of the homologous TRPM7 chanzyme is localized to unique intracellular vesicles. These vesicles are capable of accumulating Zn 2+ and releasing it via a TRPM7-dependent mechanism (15 ] may initiate the kinase domain release mechanism. In the present study, we focused on investigating the targets of released, functional TRPM6 kinase. Future studies will be necessary to further delineate the mechanisms underpinning the regulation of M6CK cleavage, potentially via local [Zn 2+ ]-activated metalloproteases. We found that M6CKs accumulate in the nucleus, and therefore investigated a nuclear-delimited function for the TRPM6 kinase. As demonstrated by genomic inactivation of TRPM6 kinase activity, M6CKs are involved in transcriptional regulation of more than 2,000 genes in 293T cells. TRPM7 also regulates gene transcription in a set of target genes that are distinct from that of TRPM6 (9) . We speculate that TRPM6 and TRPM7 channels destine cells for the expression of divergent transcriptomes via the action of their cleaved kinases. However, because the channeldependent transcriptomes were studied in cells with different epigenetic landscapes (embryonic stem cells for TRPM7 and embryonic kidney cells for TRPM6) and cells may vary substantially in a variety of factors in the TRPM6/7 pathways, further studies are necessary to understand the initiation and consequences of these transcriptional changes. Given M6CK's nuclear localization, it was not surprising that our TRPM6 interactome contained an array of nuclear proteins. Among several putative interactors, those most abundantly represented were subunits of the methylosome molecular complex, including PRMT5, WDR77, and ICLN. Endogenous M6CKs also bind these proteins. The principal component of the methylosome is the protein arginine methylase PRMT5, an enzyme that symmetrically dimethylates arginine residues (19) . In recent years, the study of histone arginine methylation has attracted great attention. Studies have revealed a critical role for this mechanism in epigenetically controlled cellular processes (30) and the functional significance of specific histone methylation (20) (21) (22) (23) 31) . WDR77 is required for substrate specificity (32) , and may define PRMT5-dependent histone methylation targets (22, 33, 34) . ICLN has been shown to modulate PRMT5-dependent histone methylation (33, 35, 36) , but its precise function is unknown. We found in vivo that M6CK phosphorylates S/T residues of histones adjacent to arginines known to be methylated by PRMT5. Moreover, this phosphorylation substantially attenuated symmetric methylation of these arginines. Thus, our primary hypothesis is that M6CK phosphorylates histone S/T residues near arginines methylated by PRMT5. M6CK's association with PRMT5, WDR77, and ICLN may target M7CK to a specific genomic location to provide site-specific histone phosphorylation that attenuates the effect of the local epigenetic arginine-methylation mark. Our observation of methylation/phosphorylation cross-talk in vivo is directly confirmed by the observation that PRMT5-mediated in vitro methylation of Arg3 in H2A and H4 synthetic peptides was blocked by the phosphorylation of H2A/H4 Ser1 (37) . It is also feasible that histone phosphorylation by M6CK serves as an independent epigenetic mark. Further genome-wide studies are required to reveal the correlation between the location of PRMT5-dependent histone methylation and M6CK-dependent histone phosphorylation.
Methylation of histone arginine residues is important in regulation of cell-cycle progression, transcription, DNA repair, and cellular differentiation (19) . M6CK's interaction with the PRMT5 molecular complex and inhibition of PRMT5-directed histone methylation by M6CK-directed phosphorylation potentially implicate TRPM6 in the regulation of these functions, opening the door to exciting future studies. In particular, PRMT5-mediated posttranslational histone modification significantly affects gene expression and ultimately induces abnormal cell growth and proliferation (38, 39) . Overexpression or dysregulation of PRMT5 has been reported in a number of cancers, including ovarian, breast, lung, lymphoid, lymphoma, melanoma, colon, gastric, prostate, and bladder cancer and germ cell tumors (13, 40, 41) . Negative regulation of histone arginine methylation by M6CK raises the possibility that TRPM6 could be used as an endogenous PRMT5 inhibitor to suppress some tumors.
Finally, the present study suggests a much wider role for TRPM6 than magnesium homeostasis, as suggested by the severe phenotype found in TRPM6 −/− mice. Our data support a mechanism in which histone posttranslational modifications by the channel-dependent TRPM6 kinase contribute to the regulation of transcriptional activity of many other genes affecting development.
Materials and Methods
Cell Culture. LoVo (human colon; ATCC, CCL-229) and 293T (human embryonic kidney; ATCC, CRL-3216) cell lines were maintained according to ATCC guidelines. HuH6 (human hepatoblastoma) cells (CVCL_1296; a generous gift of Arlin Rogers, Tufts University, North Grafton, MA) were cultured in DMEM, 10% FBS. 293T cells stably expressing tagged TRPM6 were obtained by selection with 1 μg/mL puromycin or 200 μg/mL hygromycin and cloned by limiting dilution. After testing the protein expression by WB and immunofluorescence, 5 to 10 independent clones with similar proliferation rates and protein expression were combined and used for experiments. Biochemical Procedures. For TRPM6 and M6CK immunoprecipitation experiments, proteins were extracted from the cells using NE-PER reagents (Pierce) supplemented with protease and phosphatase inhibitor mixture (Pierce); membrane, cytosolic, and nuclear extracts were combined. For histone extraction, the cell pellet was lysed in NI buffer (20 mM Tris, 50 mM NaCl, 1.5 mM MgCl 2 , 0.5% Triton X-100) containing protease and phosphatase inhibitor mixture. The insoluble pellet was washed with NI buffer and solubilized in SDS gel-loading buffer with brief sonication. For Arg-me2 WB, histones were dephosphorylated with λ-phosphatase as described (43) . GST-M6CK protein was purified from expressing BL21 bacteria using glutathione Sepharose (GE Healthcare) as described (9) . Purification of PRMT5, WDR77, and ICLN proteins was as described (44, 45) .
Tandem Affinity Purification and Mass Spectrometry. 293T cells stably expressing TRPM6-FLAG-HA were lysed as described above for IP experiments. Tagged TRPM6 was bound to FLAGM2-agarose (Sigma) and extensively washed with BW buffer (10 mM Tris, 150 mM NaCl, 1.5 mM MgCl 2 , 0.5% Nonidet P-40, protease and phosphatase inhibitor mixture, pH 7.4). Bound proteins were eluted with 1 mg/mL FLAG peptide in BW buffer. FLAG-eluted proteins were bound to HA-agarose (Roche) and washed, and bound proteins were eluted with 1 mg/mL HA-peptide. Purified proteins were pelleted by chloroform/methanol and solubilized in gel-loading SDS buffer. After separation by SDS/PAGE, proteins were stained with Coomassie blue, excised, and in-gel-digested with trypsin. Mass spectrometry analyses used a Thermo Fisher Orbitrap Elite mass spectrometer in the proteomic core facility at the Whitehead Institute for Biomedical Research.
Antibodies. Rabbit polyclonal αM6C14 antibody was derived against a peptide of the C-terminal 14 amino acids (RETGRNSPEDDMQL) of human TRPM6, affinity-purified over immobilized antigen, and used for IP of endogenous TRPM6. Mouse monoclonal TRPM6 antibody (Santa Cruz; sc-365536) was used for WB of the immunoprecipitated TRPM6. Rabbit PRMT5 and WDR77 antibodies were as described (44, 45 -TATGT-TGCTCGCAGGGCTGTTG-3′   PLTP: forward: 5′-TTGGGAGCATTGTCCTGCTGAG-3′, reverse: 5′-TAGCAG-TGACAGAGATGGTGGTG-3′   TERT: forward: 5′-CGACATGGAGAACAAGCTGT-3′, reverse: 5′-AGGTGA-GACTGGCTCTGAT-3′   IFTM2: forward: 5′-CCACATTGTGCAAACCTTCTCTCC-3′, reverse: 5′-TGCTCCT-CCTTGAGCATCTCGTAG-3′ CRISPR-Cas9-Mediated Genome Editing. CRISPR-Cas9-mediated genome editing in 293T cells was performed using homology-directed repair (46) . The optimal CRISPR-Cas9 cleavage site was chosen using DESKGEN software (www.deskgen.com). Synthetic CRISPR-Cas9 RNA (crRNA), synthetic transactivating crRNA (tracrRNA), recombinant purified Streptococcus pyogenes Cas9 nuclease (spCas9) protein, and 200-nt synthetic donor single-stranded DNA (ultramer) were purchased from IDT and transfected into cells using CRISPRMAX (Invitrogen) or nucleofection (Lonza) as described (47) . Donor DNA contained desirable modifications of the genomic sequence (stop codons, coding nucleotide mutations, or additional coding sequences) or silent mutations to make unique PCR priming sites for genotyping and to introduce unique restriction sites for homo/heterozygosity tests. To increase the homologous recombination rate, cells were synchronized in G2/M phase using 200 ng/mL nocodazole (48) for 16 h before transfection. Transfected cells were kept in media containing HDR enhancer, 10 μM RS-1 (49), for 2 d and then cloned by limiting dilution. Genomic DNA extracts (Epicentre) from clonal cells were genotyped by PCR with one primer unique for the incorporated donor and another for annealing with the genomic sequence outside the donor sequence. Genomic DNA from positively genotyped clones was PCR-amplified with primers annealing 100 to 200 nt outside the donor sequence. Amplified fragments were digested with restriction enzyme to identify clones with donor-specific unique restriction sites integrated into both chromosomes. Genomic DNA fragments of selected clones were PCR-amplified with primers annealing 100 to 200 nt outside the donor sequence, cloned into pJet1.2, and sequenced. Clones with the predicted donor incorporation were used in further experiments. Target sequence: 5′-ACTTGAAGAAAGCAATCAACAGG-3′. Donor sequence (contains a PvuI unique site; in bold): 5′-GTTTGTTC-AAGCCAGCCATCCTGCCCTCCTGGTTCTTTTCTTACTCCATTCTTGCAAGCTGTC-TACCTCTTCGTGCAATATATCATCATGGTATTCGCACCGATCGCGTTCTTCAAGT-AGGTTATTTCAATTAAATATGATTATTTAAATAAGAAATGTGGGCAGATATGTT-GAGTAGATTCACATGTACTTTGAGTATG-3′.
Genotyping primers: forward: 5′-GGTATTCGCACCGATCGCG-3′, reverse: 5′-TCACTGTTTCCCATGCTCCA-3′.
Homo/heterozygosity primers: forward: 5′-ATGGTATTCTGTGCAGTTAAT-GTG-3′, reverse: 5′-TTATTTCACTGTTTCCCATGCTCC-3′.
Kinase mutation: nucleotides AAG (5410 to 5412 of NM_017662 coding)>GCG; amino acid K1804A. Cas9 cleavage site: Chr9[74,782,376], TRPM6 exon 34.
Target sequence: 5′-TTCTTCCTGAGGTTGTGCGG-3′. Donor sequence (contains a HindIII unique site; in bold): 5′-TGGATG-GGGGCCTCCGTAAAGCTATGAGAGTCGTCAGCACTTGGTCTGAGGATGACATT-CTCAAGCCGGGACAAGTTTTCATTGTCGCAAGCTTCTTGCCAGAGGTAGTCAG-AACATGGCATAAAATCTTCCAGGAGAGCACTGTGCTTCATCTTTGCCTCAGGG-TAA-GTCTGAAACTCAGAGACCCATAGCCCAGAGGG-3′.
Genotyping primers: forward: 5′-TCTCCCCTTCCCCACATCTA-3′, reverse: 5′-TACCTCTGGCAAGAAGCTTGC-3′.
Homo/heterozygosity primers: forward: 5′-AGTCCCATTCTCCTCTGGTCA-3′, reverse: 5′-AATAGGCTCCCCTTTGGGTT-3′.
